These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22449148)

  • 1. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
    Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
    Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
    Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Vaklavas C; Forero-Torres A
    Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
    Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
    Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
    Scott LJ
    Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.
    Veleanu L; Lamant L; Sibon D;
    N Engl J Med; 2024 Jun; 390(22):2129-2130. PubMed ID: 38865667
    [No Abstract]   [Full Text] [Related]  

  • 11. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
    Kim SJ; Do YR; Lee HS; Lee WS; Kong JH; Kwak JY; Eom HS; Moon JH; Yi JH; Lee JO; Jo JC; Yang DH
    Blood Res; 2023 Dec; 58(4):194-200. PubMed ID: 38031473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
    Noguchi K; Ikawa Y
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
    Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
    Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.
    Indhuja MV; Kesana S; Mehra N; Karunakaran P; Rajan AK; Radhakrishnan V; Jayachandran PK
    South Asian J Cancer; 2024 Apr; 13(2):121-125. PubMed ID: 38919655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
    Prokoph N; Larose H; Lim MS; Burke GAA; Turner SD
    Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29601554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma].
    Michot JM; Lazarovici J
    Rev Prat; 2023 Jun; 73(6):641-650. PubMed ID: 37458554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
    Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
    Rigaud C; Knörr F; Brugières L; Woessmann W
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.
    Furtado M; Rule S
    Clin Med Insights Oncol; 2012; 6():31-9. PubMed ID: 22253553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
    Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ
    Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.